Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
SNSS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.43%203.201.2%$410.88m
GILDGilead Sciences, Inc.
0.29%73.880.9%$388.27m
CELGCelgene Corporation
-0.26%87.381.2%$331.13m
BIIBBiogen Inc.
0.60%338.911.2%$285.04m
ILMNIllumina, Inc.
-0.15%350.373.5%$238.24m
REGNRegeneron Pharmaceuticals, Inc.
-1.19%383.702.6%$211.99m
EXASExact Sciences Corporation
1.90%74.1425.3%$196.59m
VRTXVertex Pharmaceuticals Incorporated
-0.29%176.601.9%$158.10m
SRPTSarepta Therapeutics, Inc.
-1.06%151.9516.4%$124.69m
AAgilent Technologies, Inc.
0.93%69.571.5%$120.73m
ALXNAlexion Pharmaceuticals, Inc.
0.95%121.972.0%$110.07m
VKTXViking Therapeutics, Inc.
0.98%19.650.9%$100.12m
NKTRNektar Therapeutics
-2.81%56.695.6%$93.69m
ALNYAlnylam Pharmaceuticals, Inc
1.14%94.829.7%$93.23m
BMRNBioMarin Pharmaceutical Inc.
0.21%99.774.4%$92.72m

Company Profile

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.